Showing 1407 results
-
Press release /Biologics License Application (BLA) submission supported by Phase III RATIONALE 302 trial, which met primary endpoint of improvement in overall survival (OS) in people with advanced or metastatic…
-
Press release /Data show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy[1] Recent milestones for…
-
Press release /Overall response rate at 3 months was 47% (7/15) in diffuse large B-cell lymphoma and 73% (8/11) in follicular lymphoma Successful technology transfer enabling commercial scale-up of CTL019…
-
Media Library / -
Media Library / -
Press release /Farydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with…
-
Press release /82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T…
-
Press release /Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary…
-
Press release /Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1…